The 36-month beta value for KURA is at 0.84. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KURA is 64.93M, and currently, shorts hold a 16.64% of that float. The average trading volume for KURA on September 20, 2024 was 665.97K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KURA) stock’s latest price update
Kura Oncology Inc (NASDAQ: KURA) has experienced a rise in its stock price by 4.05 compared to its previous closing price of 20.26. However, the company has seen a gain of 5.98% in its stock price over the last five trading days. globenewswire.com reported 2024-09-17 that SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership.
KURA’s Market Performance
KURA’s stock has risen by 5.98% in the past week, with a monthly rise of 4.98% and a quarterly rise of 3.74%. The volatility ratio for the week is 4.98% while the volatility levels for the last 30 days are 4.00% for Kura Oncology Inc. The simple moving average for the past 20 days is 4.70% for KURA’s stock, with a 9.21% simple moving average for the past 200 days.
Analysts’ Opinion of KURA
Many brokerage firms have already submitted their reports for KURA stocks, with Mizuho repeating the rating for KURA by listing it as a “Buy.” The predicted price for KURA in the upcoming period, according to Mizuho is $26 based on the research report published on December 22, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see KURA reach a price target of $31. The rating they have provided for KURA stocks is “Buy” according to the report published on August 11th, 2023.
Scotiabank gave a rating of “Sector Perform” to KURA, setting the target price at $10.50 in the report published on July 27th of the previous year.
KURA Trading at 3.92% from the 50-Day Moving Average
After a stumble in the market that brought KURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.78% of loss for the given period.
Volatility was left at 4.00%, however, over the last 30 days, the volatility rate increased by 4.98%, as shares surge +5.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.69% upper at present.
During the last 5 trading sessions, KURA rose by +5.98%, which changed the moving average for the period of 200-days by +111.65% in comparison to the 20-day moving average, which settled at $20.19. In addition, Kura Oncology Inc saw 46.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KURA starting from Bair Teresa Brophy, who sale 2,615 shares at the price of $22.15 back on May 20 ’24. After this action, Bair Teresa Brophy now owns 68,979 shares of Kura Oncology Inc, valued at $57,916 using the latest closing price.
DOYLE THOMAS JAMES, the SVP, Finance & Accounting of Kura Oncology Inc, sale 2,318 shares at $17.80 during a trade that took place back on Jan 29 ’24, which means that DOYLE THOMAS JAMES is holding 48,093 shares at $41,262 based on the most recent closing price.
Stock Fundamentals for KURA
Current profitability levels for the company are sitting at:
- -154.5 for the present operating margin
- 0.32 for the gross margin
The net margin for Kura Oncology Inc stands at -143.11. The total capital return value is set at -0.41. Equity return is now at value -39.27, with -36.00 for asset returns.
Based on Kura Oncology Inc (KURA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -14.21. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -122.48.
Currently, EBITDA for the company is -164.96 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 1249.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.94.
Conclusion
In conclusion, Kura Oncology Inc (KURA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
